Want to join the conversation?
Pharmaceutical giant $PFE said it received positive topline phase 3 trial results comparing Xalkori (crizotinib), a type of anti-cancer drug, to chemotherapy in untreated East-Asian patients with ALK-positive advanced non-small cell lung cancer.
$YHOO is reporting today after market close. Nobody cares about this stock.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.